A review of epidermal growth factor receptor/HER2 inhibitors in the treatment of patients with non-small-cell lung cancer

Keyphrases

• Epidermal Growth Factor Receptor 100%
• Non-small Cell Lung Cancer (NSCLC) 100%
• HER2 Inhibitors 100%
• Acquired Resistance 50%
• Survival Rate 50%
• Clinical Efficacy 50%
• Human Epidermal Growth Factor Receptor 2 (HER2) 50%
• Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC) 50%
• Novel Agents 50%
• Small Patients 50%
• Poor Survival 50%
• Clinical Development 50%
• Erlotinib 50%
• Epidermal Growth Factor Receptor Inhibitors 50%
• Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor (EGFR-TKI) 50%
• Resistance Development 50%
• Recurrent Non-small Cell Lung Cancer 50%
• Global Health Issue 50%
• Irreversible Inhibitor 50%

Pharmacology, Toxicology and Pharmaceutical Science

• Epidermal Growth Factor Receptor 100%
• Non Small Cell Lung Cancer 100%
• Epidermal Growth Factor Receptor Kinase Inhibitor 66%
• Survival Rate 33%
• Erlotinib 33%
• Diseases 33%